EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average “Buy” Rating from Analysts
EyePoint Pharmaceuticals, Inc. Stock (NASDAQ: EYPT – Get a rating) have been assigned a consensus “Buy” rating by the five research companies that currently cover the company, Market assessments reports. One research analyst gave the stock a hold rating and four gave the company a buy rating. The 1-year average price target among brokers who have covered the stock over the past year is $23.67.
A number of analysts have weighed in on EYPT shares. HC Wainwright reiterated a “buy” rating and posted a $24.00 price target on EyePoint Pharmaceuticals shares in a research report on Friday, March 4. StockNews.com began covering EyePoint Pharmaceuticals in a research report on Thursday, March 31. They issued a “holding” rating on the stock. Zacks Investment Research upgraded EyePoint Pharmaceuticals from a “hold” rating to a “buy” rating and set a price target of $12.00 on the stock in a Monday, May 9 research report. Finally, Cantor Fitzgerald reiterated an “overweight” rating on EyePoint Pharmaceuticals shares in a Friday, March 4 research report.
Several institutional investors and hedge funds have recently changed their holdings in the company. Franklin Resources Inc. increased its stake in shares of EyePoint Pharmaceuticals by 13.5% during the third quarter. Franklin Resources Inc. now owns 3,174,337 shares of the company valued at $33,076,000 after acquiring an additional 377,664 shares during the period. Suvretta Capital Management LLC increased its stake in shares of EyePoint Pharmaceuticals by 15.5% during the first quarter. Suvretta Capital Management LLC now owns 2,909,407 shares of the company valued at $35,349,000 after acquiring an additional 389,707 shares during the period. RA Capital Management LP increased its stake in EyePoint Pharmaceuticals by 76.8% in the third quarter. RA Capital Management LP now owns 2,210,506 shares of the company valued at $23,033,000 after purchasing an additional 960,506 shares during the period. Adage Capital Partners GP LLC increased its stake in EyePoint Pharmaceuticals by 10.6% in the fourth quarter. Adage Capital Partners GP LLC now owns 1,950,000 shares of the company valued at $23,868,000 after purchasing an additional 186,969 shares during the period. Finally, BlackRock Inc. increased its stake in EyePoint Pharmaceuticals by 5.9% in the first quarter. BlackRock Inc. now owns 1,526,153 shares of the company valued at $18,543,000 after purchasing an additional 85,522 shares during the period. 87.67% of the shares are currently held by institutional investors and hedge funds.
Shares of EYPT traded down $0.02 on Friday, hitting $9.51. 69,413 shares of the stock have been traded, compared to its average volume of 115,622. The company has a market capitalization of $323.82 million, a price-to-earnings ratio of -4.57 and a beta of 1 ,16. The company has a debt ratio of 0.17, a current ratio of 6.87 and a quick ratio of 6.77. EyePoint Pharmaceuticals has a 12-month low of $7.30 and a 12-month high of $21.50. The stock’s 50-day moving average price is $11.74 and its 200-day moving average price is $12.17.
EyePoint Pharmaceuticals (NASDAQ: EYPT – Get a rating) last released its quarterly earnings data on Wednesday, May 4. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analyst consensus estimates of ($0.50) by ($0.02). The company posted revenue of $9.29 million for the quarter, versus a consensus estimate of $10.35 million. EyePoint Pharmaceuticals had a negative net margin of 174.09% and a negative return on equity of 47.60%. In the same quarter a year earlier, the company posted ($0.50) earnings per share. As a group, equity research analysts expect EyePoint Pharmaceuticals to post earnings per share of -2.41 for the current fiscal year.
EyePoint Pharmaceuticals Company Profile (Get a rating)
EyePoint Pharmaceuticals, Inc, a pharmaceutical company, develops and markets ophthalmic products for the treatment of eye diseases in the United States, China and the United Kingdom. The Company offers ILUVIEN, a sustained-release injectable micro-insert for the treatment of diabetic macular edema; YUTIQ, an intravitreal fluocinolone acetonide implant for intravitreal injection for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye; and DEXYCU, an intraocular suspension of dexamethasone, for the treatment of postoperative eye inflammation, including treatment after cataract surgery.
Get news and reviews for EyePoint Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for EyePoint Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.